Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS)

Compare
18.64
-0.06
(-0.32%)
At close: 3:00:03 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
NameTitlePayExercisedYear Born
Mr. Qiuhua Yang Executive Chairman -- -- 1972
Mr. Yongzhong Li VP & Executive Director 6.03M -- 1970
Mr. Ming Dong Executive Director -- -- 1976
Mr. Tao Zhong VP, Board Secretary & Joint Company Secretary -- -- 1972
Mr. Dongming Li Vice President -- -- 1969
Ms. Shuai Shao Vice President -- -- 1988
Dr. Shunjiang Yu Chief Medical Officer -- -- --
Ms. Pui Kiu Wong Joint Company Secretary -- -- --
Ying Ke Director & General Manager of R&D Management Center -- -- --
Linqiong Dong Securities Affairs Representative -- -- --

Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceutical Building
No. 200 Taicang Road
Shanghai, 200020
China
86 21 6373 0908 https://www.sphchina.com
Sector: 
Healthcare
Full Time Employees: 
49,402

Description

Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer's, and inflammatory bowel diseases. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. The company was incorporated in 1994 and is headquartered in Shanghai, China.

Corporate Governance

Shanghai Pharmaceuticals Holding Co., Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 24, 2025 at 10:59 AM UTC - April 28, 2025 at 12:00 PM UTC

Shanghai Pharmaceuticals Holding Co., Ltd Earnings Date

Recent Events

September 24, 2024 at 12:00 AM UTC

Ex-Dividend Date